Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:01 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma
NCT05788289 · Memorial Sloan Kettering Cancer Center · PHASE2 · terminated · last registry update 2025-05-25 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Slow accrual rate” | – | Registry record, Memorial Sloan Kettering Cancer Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CD19 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-05-20Phase 3 first posted: Amgen, Inebilizumab + Placebo (NCT07598825)
- 2026-05-13Results posted on the registry: Amgen, Blinatumomab (NCT06649006)
- 2026-05-06Phase 3 first posted: Merck Sharp & Dohme LLC, MK-1045 + Blinatumomab (NCT07570173)
- 2026-04-07Also stopped (withdrawn): Memorial Sloan Kettering Cancer Center, Epcoritamab + Lenalidomide (NCT07030699)
- 2026-03-18Phase 3 first posted: Kite, A Gilead Company, KITE-753 + Axicabtagene Ciloleucel (NCT07479797)
- 2026-03-18Also stopped (withdrawn): Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, Cyclophosphamide + Doxorubicin (NCT06313996)
- 2026-03-17Phase 3 first posted: Charite University, Berlin, Germany, Inotuzumab ozogamicin (INO) + Blinatumomab (NCT07476729)
- 2026-03-10Results posted on the registry: Amgen, inebilizumab + IV Placebo (NCT04524273)
- 2026-03-10Results posted on the registry: Kite, A Gilead Company, Brexucabtagene Autoleucel + Cyclophosphamide (NCT05537766)
- 2026-03-10Also stopped (terminated): Kite, A Gilead Company, Brexucabtagene Autoleucel + Cyclophosphamide (NCT05537766)
- 2026-03-06Also stopped (terminated): Imugene Limited, CF33-CD19 IT Monotherapy + CF33-CD19 IV Monotherapy (NCT06063317)
- 2026-03-04Results posted on the registry: St. Jude Children's Research Hospital, Cyclophosphamide + Fludarabine (NCT03849651)
- 2026-02-27Also stopped (terminated): Jonsson Comprehensive Cancer Center, Anakinra + Axicabtagene Ciloleucel (NCT04205838)
- 2026-02-04Also stopped (terminated): Incyte Corporation, tafasitamab + parsaclisib (NCT04809467)
- 2026-01-29Results posted on the registry: Incyte Corporation, tafasitamab + parsaclisib (NCT04809467)
- 2026-01-29Results posted on the registry: Patrick C. Johnson, MD, ACALABRUTINIB + LISOCABTAGENE MARALEUCEL (NCT05583149)
- 2026-01-23Results posted on the registry: Masonic Cancer Center, University of Minnesota, KYMRIAH + YESCARTA (NCT03642626)
- 2025-12-23Results posted on the registry: Kite, A Gilead Company, Axicabtagene ciloleucel + Cyclophosphamide (NCT03105336)
- 2025-12-22Phase 3 first posted: Bambino Gesù Hospital and Research Institute, Ruxolitinib + Blinatumomab (NCT07297914)
- 2025-11-13Also stopped (suspended): City of Hope Medical Center, Chimeric Antigen Receptor T-Cell Therapy + Tafasitamab (NCT05993611)
- 2025-11-10Results posted on the registry: University of California, San Diego, blinatumomab + pembrolizumab (NCT03160079)
- 2025-10-31Phase 3 first posted: Amgen, Blinatumomab + Blinatumomab (NCT07223190)
- 2025-10-23Results posted on the registry: Fred Hutchinson Cancer Center, Anakinra (NCT04359784)
- 2025-10-03Also stopped (withdrawn): Karyopharm Therapeutics Inc, Selinexor + Rituximab (NCT04607772)
- 2025-09-23Phase 3 first posted: Lyell Immunopharma, Inc., rondecabtagene autoleucel + axicabtagene ciloleucel (NCT07188558)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision